Introduction
Multiple myeloma is a disease of the elderly with median age at time of diagnosis of 70 years. The optimal treatment regimen for patients in the seventh and eighth decades of life with multiple myeloma is not clear. Uncertainty regarding optimal therapy is due in part to significant under-representation in clinical trials and the heterogeneity of this population.
Autologous stem cell transplantation (ASCT) is an accepted therapy for multiple myeloma patients o65 years of age. [1] [2] [3] High-dose chemotherapy is increasingly being offered to older patients with multiple myeloma as transplant-related mortality (TRM) has decreased with the use of peripheral stem cells and growth factor support ( Table 1) . The upper age limit of transplantation has been challenged by several studies which have demonstrated efficacy and tolerability of high-dose therapy in selected patients 460 years old. [4] [5] [6] [7] Although these studies have paved the way for increased treatment options for elderly patients with multiple myeloma, many questions remain unanswered.
ASCT in elderly patients presents a unique set of challenges in the research and clinical setting. The first challenge is developing an evidenced-based process of patient selection to identify patients who may potentially benefit from and tolerate high-dose therapy. Both patientspecific characteristics such as comorbidity and measures of physiologic reserve as well as tumor-specific factors need to be explored. This concept of patient stratification is critically important in trying to define the role of physiologic aging rather than chronologic aging in the context of multiple myeloma therapy. Second, preparative and conditioning regimens that maximize efficacy and minimize toxicity in an older population will need to be assessed. Finally, it will be important to consider additional outcome measures that may be more relevant to the elderly population such as prevention of disability and quality of life as future trials are designed. The optimal therapy for elderly patients with multiple myeloma will need to be individualized to account for the heterogeneity of baseline characteristics as well as a broader range of clinical outcomes relevant to this population.
Multiple myeloma and age

Epidemiology
Multiple myeloma is a disease of the elderly with a median age of 70 years reported in the Surveillance Epidemiology and End Results (SEER) database from 1997 to 2001. The incidence of multiple myeloma increases with age ( Figure 1 ) with over 50% of new cases diagnosed in patients X65 years of age (SEER website). The number of elderly patients with myeloma is expected to increase with the aging of the US population translating into more complex and challenging treatment decisions in clinical practice.
Impact of age on prognosis
Age has a negative impact on prognosis in multiple myeloma in unselected populations. The SEER registry statistics from 1995 to 2001 report 5-year relative survival rates of 42.9 and 25.2% for patients o65 and X65 years of age, respectively (SEER website) (Figures 2 and 3) . Survival is dramatically decreased in the X75-year-old population. In a retrospective review of 1027 patients with newly diagnosed multiple myeloma evaluated at the Mayo Clinic, Kyle et al. 8 reported a median age of 66 years with 38% of patients X70 years of age. The median duration of survival was 40.5 months for patients younger than 70 years and 26.4 months for those 70 years and older. In multivariate analysis, age remained one of the most important negative prognostic factors. Two additional series restricted to patients X70 years of age reported decreased survival associated with advanced age in patients treated with conventional therapy. 9, 10 Why does age negatively impact prognosis in multiple myeloma? To date, no clear differences in the biology of disease owing to age have been elucidated in multiple myeloma. Several studies have reported no significant differences in older patients with regard to presenting biologic features including hematologic parameters, stage of disease, beta 2 microglobulin level or renal function. [9] [10] [11] A recent analysis of 783 patients has demonstrated possible genetic differences between younger and older patients with multiple myeloma. 12 In this study, loss of chromosome Y and þ 5 were more common in elderly patients. However, there is no evidence that clinically significant cytogenetic abnormalities are age dependent. Available evidence, therefore, does not support the idea that older patients have more aggressive disease.
The negative impact of age on prognosis was reviewed by Mileshkin and Prince 13 and related to a combination of factors including comorbidity, performance status, decreased physiologic reserve, social support, referral bias and potentially, undertreatment. Significant concurrent comorbidity was recorded in 33.8% of patients in an unselected cohort aged 70 and above with newly diagnosed multiple myeloma 10 and likely plays a large role in treatment decisions and toxicity. Impaired physiologic reserve including altered immune function and drug metabolism may also contribute to worse outcomes in older myeloma patients. Poor functional status on the Eastern Cooperative Oncology Group scale ((ECOG) performance status score X2) is more common in older patients with multiple myeloma and is independently associated with decreased survival. 8, 10 The impact of inadequate social support, referral bias and treatment bias can be speculated upon but have not yet been studied in this population.
Selected elderly patients benefit equally from treatment Despite the negative impact of age on prognosis in unselected populations, there have been multiple small studies which have reported equivalent response to therapy and survival rates for selected older patients compared to younger patients treated with similar therapy. 11, [14] [15] [16] Most of these analyses were conducted with patients who were enrolled on clinical trials. These initial reports of equal benefit from equal treatment in a selected elderly population have resulted in increased interest in pursuing more aggressive therapies in older patients in an attempt to improve survival outcomes. 
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Is stem cell mobilization feasible in older patients with multiple myeloma? Successful treatment with high-dose chemotherapy and ASCT depends upon adequate stem cell mobilization and ultimately stem cell engraftment. Several studies have addressed the impact of age on mobilization and engraftment in patients with multiple myeloma. [17] [18] [19] Guba et al. 19 reviewed 225 multiple myeloma patients mobilized with high-dose cyclophosphamide and hematopoietic growth factors and found no differences in median CD34 þ cell count and median time to engraftment by age (20-49, 50-59 and X60 years) when adjusted for prior therapies. For age group X60 years, the median number of CD34 þ cells was 10 Â 10 6 /kg with median time to engraftment of granulocytes 4500/ml and platelets 450 000/ml of 11 and 14 days, respectively. A second study evaluated the impact of age on stem cell mobilization and engraftment in 117 patients using granulocyte colony stimulating factor alone. 17 In this study, increasing age did not impact stem cell procurement but was associated with prolonged platelet recovery in multivariate analysis. In a small study comparing consecutive stem cell mobilization in patients younger than 60 vs those 60 years and older, there was evidence of a significantly decreased number of circulating CD34 þ cells at the time of pheresis in the older patients (median 27 725 cells/ml vs 11 981 cell/ml). This translated into decreased numbers of CD34 þ cells in the graft (median 6.5 Â 10 6 /kg vs 2.3 Â 10 6 /kg) and slightly prolonged leukocyte and platelet recovery. 18 Overall, these studies suggest that whereas stem cell mobilization is feasible in older patients, further attention will need to be focused on adequate stem cell yield and engraftment in the elderly population particularly as upper age limits for transplantation increase.
Future studies will need to prospectively compare toxicity and efficacy of various mobilization regimens including high-dose cyclophosphamide, reduced dose cyclophosphamide and granulocyte colony stimulating factor alone in the elderly population. At the present time there is insufficient evidence to promote the superiority of any specific mobilization regimen for older adults. Is high-dose chemotherapy with stem cell support feasible in older adults with multiple myeloma?
The feasibility of high-dose chemotherapy with ASCT in older adults has been repeatedly addressed in the literature over the past 15 years with continued redefinition of upper age limits. In 1995, Rapoport et al. 20 reported on the efficacy of autotransplantation in patients over 40 years of age. Since that time, researchers have challenged upper age limits and have begun to investigate the feasibility and efficacy of autologous transplantation in the upfront treatment of multiple myeloma in patients in the sixth and seventh decades of life.
Most studies focusing on autologous transplantation in older adults are retrospective. Several case control studies have been published which address the feasibility and efficacy of ASCT in older adults compared to younger counterparts treated with similar therapy (Table 2) . Four case comparison studies reported equivalent survival in an older cohort compared to younger controls. 7, [22] [23] [24] In 1999, Siegel et al. 7 compared 49 patients X65 years of age with younger patients matched for known prognostic factors treated with melphalan 200 mg/m 2 as the conditioning regimen. In this comparison, event-free survival and overall survival were similar between groups despite a lower complete response rate in the older patients. Subsequently, Sirohi et al. and Jantunen et al. 22, 24 reported similar results using high-dose melphalan as a conditioning regimen in single institution retrospective comparison studies. Terpos et al. 26 retrospectively analyzed the effect of age on overall and progression-free survival in 127 patients using age cutoffs of 55, 60 and 65 years and found no significant differences in outcomes. Reece et al. 23 used tumor registry data to select 110 patients X 60 years of age and reported no difference in overall survival, disease-free survival and TRM compared to 382 younger patients. In contrast, Dumontet et al. 21 reported decreased disease-free survival in a cohort of patients X60 years of age treated with ASCT. Lenhoff et al. 25 also reported a negative impact of age X60 years in a population-based study of ASCT with high-dose melphalan.
Only one published study has specifically evaluated the feasibility of ASCT in multiple myeloma patients X70 years of age. 4 In this prospective feasibility study, the first 25 patients were treated with melphalan 200 mg/m 2 and experienced excess TRM at a rate of 16%. The melphalan dose was decreased to 140 mg/m 2 for the remaining 45 patients with a decrease in TRM to 2%. Forty-four percent of patients completed a tandem transplant regimen. The reported 3-year overall survival rate was 31710%.
The impact of age on transplant-related toxicity is inconsistent in the small body of literature available to date (Table 3 ). Most studies have demonstrated similar TRM in older patients compared to younger patients when treated with the same conditioning regimens. 5, [22] [23] [24] [25] 26 The most striking increase in TRM was reported by Badros et al. 4 in patients over age 70 treated with melphalan 200 mg/m 2 . Increased diarrhea and mucositis associated with age was reported in one study. 24 Preliminary data provided by the Center for International Blood and Marrow Transplant Research suggests similar TRM in older adults compared to younger age groups but patients 70 years of age and above represent only 3% of the sample (Table 4) . It is important to remember that most studies to date have evaluated small numbers of selected patients with very few individuals over the age of 70 represented.
Overall, the current available literature suggests that whereas selected older patients may benefit equally from high-dose therapy with stem cell rescue, there may me a negative impact of advancing age on response, toxicity and survival outcomes that requires further investigation.
Is high-dose chemotherapy with stem cell rescue more effective than conventional therapy in older adults with multiple myeloma? The role of high-dose chemotherapy with stem cell rescue in the upfront treatment of older adults with multiple myeloma can only be established by prospective randomized controlled trials. Lenhoff et al. 25 demonstrated a survival advantage for patients 60 years and older treated with intensive therapy compared to historic controls treated with conventional agents in a population-based analysis. Patients treated with high-dose therapy received melphalan 200 mg/m 2 . There has been no randomized trial of older Table 2 Non-randomized comparison studies of autologous bone marrow transplantation by age 6 This study demonstrated improved 3-year event-free survival (37 vs 16%, P ¼ 0.0002) and overall survival (77 vs 62%, Po0.001) favoring the intermediate dose melphalan group. Recently, Facon et al. 27 presented the unpublished results the Intergroupe Francophone du Mye´lome (IFM) 99-06 trial which compared melphalan and prednisone alone, vs melphalan with prednisone and thalidomide vs intermediate dose melphalan with stem cell rescue as upfront therapy for adults aged 65-75 considered ineligible for high-dose chemotherapy. The results presented demonstrated a significant overall survival benefit for patients randomized to the thalidomide arm. There was no significant survival advantage seen for patients treated with intermediate dose melphalan over conventional therapy in this study.
The design and results of the IFM 99-06 clinical trial highlight many important issues including, eligibility criteria and treatment modification, that need to be addressed in future research studies focused on older adults with multiple myeloma. Specifically, this study was designed to enroll older adults considered ineligible for high-dose chemotherapy and therefore evaluated the efficacy of a lower dose of melphalan as the conditioning regimen. The results of this study can only be interpreted in this context leaving the question regarding the role of highdose chemotherapy in older adults with myeloma unanswered at the present time. It would be premature to conclude that high-dose chemotherapy with stem cell support should not be offered to selected older adults with multiple myeloma.
ASCT in elderly patients with multiple myeloma -what questions do we still need to ask?
How do we develop patient selection algorithms to identify older patients that are more likely to benefit from high-dose chemotherapy? Older patients with multiple myeloma represent a very heterogenous population requiring more detailed assessment of health status before treatment determination. Eligibility criteria remain a central issue in future clinical trials focused on older adults particularly with regard to ASCT. For example, the IFM 99-06 trial included patients 'ineligible' for high-dose chemotherapy. It remains to be determined which clinical characteristics confer ineligibility for this type of therapy.
Older adults are more likely to present with increased comorbidity. 10, 28, 29 The impact of comorbidity assessment is not well established in ASCT. Comorbidity assessment with the Charlson Comorbidity Index has been shown to be predictive of increased toxicity and mortality in allogeneic transplantation. 30, 31 Sorror et al. 32 refined this index to improve sensitivity and documented the reliability and Table 3 Influence of age on transplant-related toxicity in multiple myeloma validity of this tool in allogeneic transplantation. Prospective assessment of comorbidity using established or transplant-specific indices may provide important information for development of evidence-based risk stratification in older adults evaluated for ASCT. Comorbidity assessment alone may not provide sufficient information regarding the physiologic reserve of older patients. In clinical practice it is apparent that older patients with similar age and comorbidity may differ substantially with regard to functional status. Specific measures of functional status can provide more prognostic information than comorbidity alone in older adults. 33 In older cancer patients, Extermann et al. 34 demonstrated that comorbidity and functional assessment were not well correlated and provided independent information. Careful functional assessment during pretransplant evaluation may provide added information for risk stratification. It will be important to prospectively assess the predictive value of task-specific functional assessment tools such as activities of daily living 35 and instrumental activities of daily living.
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These self-report measures are able to identify functional impairment in cancer patients with good performance scores on the ECOG scale. 37 This added discriminatory capacity may be useful to detect subtle changes reflective of decreased functional reserve.
Finally, objective measures of physical performance and cognition may be particularly useful in developing an evaluation protocol for older patients being considered for high-dose chemotherapy. Physical performance measures such as walking speed and lower extremity function are predictive of future disability, hospitalizations and mortality in the geriatric population. [38] [39] [40] These objective measures may be sensitive to subclinical disability which could be closely associated with morbidity and mortality outcomes in the setting of high-dose chemotherapy.
Do we need to tailor therapy for older adults to maximize efficacy and minimize toxicity? In addition to developing an evidence-based method of patient selection, it will be important to consider the need for tailored therapy in the elderly population. For example, the ideal dose of melphalan as a conditioning agent is not clear for older adults. There is some evidence that 200 mg/m 2 may be poorly tolerated in patients over age 70. 4 However, the recently reported IFM 99-06 trial suggests that 100 mg/m 2 given in tandem is not superior to conventional therapy. 27 Dosing strategies will need to be specifically evaluated in the elderly population in order to determine the benefit of high-dose therapy.
Future directions for tailored therapy in the elderly include the use of novel agents for induction therapy to minimize toxicity and functional decline before transplantation. Use of oral immunomodulatory agents such as thalidomide, or proteosome inhibitors before transplantation may be better tolerated than cytotoxic chemotherapy allowing for more patients to proceed with transplantation and fewer complications associated with functional decline. Older adults with multiple myeloma may benefit from unique combinations of novel agents and transplantation strategies providing aggressive therapy with minimal toxicity.
Do we need to consider additional outcome measures in clinical trials focused on older adults with multiple myeloma? The paradigm of multiple myeloma is shifting to one of chronic disease. As treatment options increase, it will be important to evaluate the impact of therapies on quality of life and disability in older adults. These secondary outcome measures will help guide treatment decisions when presented with equally efficacious therapies. In addition, the timing and sequencing of therapeutic modalities may impact quality of life without significantly affecting survival. The role of high-dose chemotherapy with stem cell rescue in the management of older adults with multiple myeloma can only be fully evaluated in the context of the impact on quality of life and disability as well as overall survival (Table 5) . 
